Taysha Gene Therapies, Inc. - Common Stock, par value $0.00001 per share (TSHA)
CUSIP: 877619106
Q2 2024 13F Holders as of 30 Jun 2024
- Type / Class
- Equity / Common Stock, par value $0.00001 per share
- Shares outstanding
- 275,000,000
- Total 13F shares
- 158,086,076
- Share change
- +17,852,154
- Total reported value
- $354,139,573
- Put/Call ratio
- 64%
- Price per share
- $2.24
- Number of holders
- 102
- Value change
- +$33,881,138
- Number of buys
- 62
- Number of sells
- 58
Quarterly Holders Quick Answers
What is CUSIP 877619106?
CUSIP 877619106 identifies TSHA - Taysha Gene Therapies, Inc. - Common Stock, par value $0.00001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 877619106:
Top shareholders of TSHA - Taysha Gene Therapies, Inc. - Common Stock, par value $0.00001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| FMR LLC |
13F
|
Company |
7.3%
|
20,110,717
|
$57,717,758 | — | 31 Mar 2024 | |
| Avoro Capital Advisors LLC |
13F
|
Company |
6.8%
|
18,650,000
|
$53,525,500 | — | 31 Mar 2024 | |
| RTW INVESTMENTS, LP |
13F
|
Company |
6.8%
|
18,593,185
|
$53,362,441 | — | 31 Mar 2024 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
4%
|
10,872,503
|
$31,204,084 | — | 31 Mar 2024 | |
| VR Adviser, LLC |
13F
|
Company |
3.3%
|
9,000,000
|
$25,830,000 | — | 31 Mar 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
2.2%
|
5,917,414
|
$16,982,978 | — | 31 Mar 2024 | |
| MORGAN STANLEY |
13F
|
Company |
1.9%
|
5,168,890
|
$14,834,714 | — | 31 Mar 2024 | |
| R.a. Session II |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
9,012,837
|
$14,690,925 | — | 12 Jul 2023 | |
| Audentes Therapeutics, Inc. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
7,266,342
|
$11,844,137 | — | 21 Oct 2022 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
1.5%
|
4,004,756
|
$11,493,650 | — | 31 Mar 2024 | |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD |
13F
|
Company |
1.3%
|
3,700,000
|
$10,619,000 | — | 31 Mar 2024 | |
| Artal Group S.A. |
13F
|
Company |
1.3%
|
3,687,548
|
$10,583,263 | — | 31 Mar 2024 | |
| ACUTA CAPITAL PARTNERS, LLC |
13F
|
Company |
1.2%
|
3,333,333
|
$9,566,666 | — | 31 Mar 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
1.1%
|
3,135,317
|
$8,998,360 | — | 31 Mar 2024 | |
| Octagon Capital Advisors LP |
13F
|
Company |
1.1%
|
3,030,000
|
$8,696,100 | — | 31 Mar 2024 | |
| BlackRock Finance, Inc. |
13F
|
Company |
0.94%
|
2,597,303
|
$7,454,260 | — | 31 Mar 2024 | |
| Polar Capital Holdings Plc |
13F
|
Company |
0.92%
|
2,518,909
|
$7,229,269 | — | 31 Mar 2024 | |
| Eversept Partners, LP |
13F
|
Company |
0.85%
|
2,325,591
|
$6,674,446 | — | 31 Mar 2024 | |
| EAGLE ASSET MANAGEMENT INC |
13F
|
Company |
0.65%
|
1,789,394
|
$5,081,878 | — | 31 Mar 2024 | |
| COWEN AND COMPANY, LLC |
13F
|
Company |
0.56%
|
1,550,000
|
$4,448,500 | — | 31 Mar 2024 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.48%
|
1,309,627
|
$3,758,630 | — | 31 Mar 2024 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
0.4%
|
1,113,232
|
$3,194,976 | — | 31 Mar 2024 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
0.4%
|
1,099,329
|
$3,156,000 | — | 31 Mar 2024 | |
| STEMPOINT CAPITAL LP |
13F
|
Company |
0.4%
|
1,087,785
|
$3,121,943 | — | 31 Mar 2024 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.39%
|
1,072,070
|
$3,076,841 | — | 31 Mar 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.39%
|
1,058,962
|
$3,039,221 | — | 31 Mar 2024 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.37%
|
1,030,657
|
$2,957,986 | — | 31 Mar 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.37%
|
1,019,791
|
$2,927,671 | — | 31 Mar 2024 | |
| Ghost Tree Capital, LLC |
13F
|
Company |
0.35%
|
950,000
|
$2,726,500 | — | 31 Mar 2024 | |
| Soleus Capital Management, L.P. |
13F
|
Company |
0.34%
|
925,000
|
$2,654,750 | — | 31 Mar 2024 | |
| Palo Alto Investors LP |
13F
|
Company |
0.3%
|
811,268
|
$2,328,339 | — | 31 Mar 2024 | |
| Sands Capital Alternatives, LLC |
13F
|
Company |
0.26%
|
724,873
|
$2,080,386 | — | 31 Mar 2024 | |
| Quantum Private Wealth, LLC |
13F
|
Company |
0.25%
|
698,520
|
$2,004,753 | — | 31 Mar 2024 | |
| Alphabet Inc. |
13F
|
Company |
0.23%
|
640,882
|
$1,839,331 | — | 31 Mar 2024 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.2%
|
552,595
|
$1,585,947 | — | 31 Mar 2024 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.15%
|
414,980
|
$1,190,000 | — | 31 Mar 2024 | |
| STATE STREET CORP |
13F
|
Company |
0.12%
|
339,520
|
$974,422 | — | 31 Mar 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.12%
|
328,500
|
$943,000 | — | 31 Mar 2024 | |
| Suyash Prasad |
3/4/5
|
CMO and Head of R&D |
—
class O/S missing
|
530,589
|
$864,860 | — | 05 Jul 2022 | |
| Kovitz Investment Group Partners, LLC |
13F
|
Company |
0.1%
|
277,778
|
$797,223 | — | 31 Mar 2024 | |
| CITIGROUP INC |
13F
|
Company |
0.09%
|
255,203
|
$732,433 | — | 31 Mar 2024 | |
| Marathon Trading Investment Management LLC |
13F
|
Company |
0.08%
|
223,900
|
$642,593 | — | 31 Mar 2024 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
0.08%
|
220,000
|
$631,400 | — | 31 Mar 2024 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.08%
|
213,946
|
$614,025 | — | 31 Mar 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.08%
|
211,395
|
$606,704 | — | 31 Mar 2024 | |
| UBS Group AG |
13F
|
Company |
0.07%
|
189,284
|
$543,245 | — | 31 Mar 2024 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
0.07%
|
188,698
|
$541,563 | — | 31 Mar 2024 | |
| Point72 Asia (Singapore) Pte. Ltd. |
13F
|
Company |
0.07%
|
181,306
|
$520,348 | — | 31 Mar 2024 | |
| TD ASSET MANAGEMENT INC |
13F
|
Company |
0.06%
|
175,600
|
$503,972 | — | 31 Mar 2024 | |
| Brevan Howard Capital Management LP |
13F
|
Company |
0.06%
|
172,769
|
$495,847 | — | 31 Mar 2024 |
Institutional Holders of Taysha Gene Therapies, Inc. - Common Stock, par value $0.00001 per share (TSHA) as of Q2 2024
As of 30 Jun 2024,
Taysha Gene Therapies, Inc. - Common Stock, par value $0.00001 per share (TSHA) was held by
102 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
158,086,076 shares.
The largest 10 holders included
FMR LLC, RTW INVESTMENTS, LP, Avoro Capital Advisors LLC, BlackRock Inc., RA CAPITAL MANAGEMENT, L.P., VR Adviser, LLC, MORGAN STANLEY, VANGUARD GROUP INC, Octagon Capital Advisors LP, and Artal Group S.A..
This page lists
104
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
106
Q2 2024 holders
102
Holder diff
-4
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 Value $ | Q2 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.